SimBioSys is a technology company.
SimBioSys has raised $15.0M across 1 funding round.
SimBioSys has raised $15.0M in total across 1 funding round.
SimBioSys has raised $15.0M in total across 1 funding round.
SimBioSys's investors include Genoa Ventures, Northpond Ventures, Kevin Love.
SimBioSys is a TechBio company developing TumorSight, a cloud-based digital precision medicine platform that uses AI and biophysical modeling to create 3D visualizations and digital twins of tumors from imaging data like DCE-MRI.[1][2] It serves clinicians, particularly breast cancer surgeons, and patients by quantifying tumor metrics such as volume, distance to anatomical structures, and heterogeneity to support preoperative planning and individualized treatment, addressing limitations of 2D biopsies and pathology.[1][2][3] The company has achieved key milestones like FDA 510(k) clearance for TumorSight Viz in January 2024 and partnerships with institutions like Mayo Clinic, driving commercial adoption at top cancer centers with 20+ employees and 10+ peer-reviewed publications.[1][3]
SimBioSys was founded in 2018 by Dr. Joe Peterson, Dr. John Cole, and Tushar Pandey (co-founder and CEO) in Champaign, Illinois, stemming from a National Cancer Institute grant discussion in a university lab at the University of Illinois.[3][6] Peterson and Cole, computational biology experts, identified a gap in oncology decision-making and envisioned software-based biophysical modeling and AI to provide deeper tumor insights without invasive procedures.[3] Pandey joined shortly after to lead commercialization; early traction included research collaborations with Mayo Clinic, UCLA, and the University of Chicago, evolving from a lab idea into a venture-backed company with a growing commercial footprint.[1][3]
SimBioSys rides the TechBio wave at the intersection of AI, computational oncology, and precision medicine, transforming 2D imaging into actionable 3D spatial biophysics insights amid rising demand for personalized cancer care.[1][2][3] Timing aligns with FDA's push for software-as-medical-device innovations and surging oncology AI investments, as tumor heterogeneity drives variable treatment responses and the need for non-invasive tools.[1][2] Market forces like expanding solid tumor markets, DCE-MRI adoption, and clinician shortages favor scalable cloud platforms; SimBioSys influences the ecosystem by setting standards for virtual tumor modeling, fostering collaborations that advance computational oncology beyond biopsies.[3][5]
SimBioSys is poised for expansion with TumorSight Viz commercialization and further FDA clearances targeting additional breast cancer utilities and solid tumors, leveraging its platform for predictive outcome algorithms.[1][2] Trends like AI-driven digital twins, multi-omics integration, and value-based care will shape growth, potentially amplifying influence through more health system partnerships and global adoption. As a leader virtualizing cancer, SimBioSys advances from visualization pioneer to full precision medicine enabler, fulfilling its mission to defeat cancer through spatial biophysics.[1][3]
SimBioSys has raised $15.0M across 1 funding round. Most recently, it raised $15.0M Series A in October 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2021 | $15.0M Series A | Genoa Ventures, Northpond Ventures, Kevin Love |